RNF6 enhances radioresistance in colorectal cancer via activating the Wnt pathway.

Q2 Medicine Journal of Buon Pub Date : 2021-09-01

Xi Zhong, Bin Zhou, Zhaoying Lv, Yong Liu

{"title":"RNF6 enhances radioresistance in colorectal cancer via activating the Wnt pathway.","authors":"Xi Zhong, Bin Zhou, Zhaoying Lv, Yong Liu","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: RNF6 is verified to promote the malignant growth of colorectal cancer (CRC) and its level is linked to prognosis in CRC patients. Radioresistance is a key factor influencing prognosis in CRC. This study aimed to uncover the potential regulation of ring finger protein 6 (RNF6) in CRC radioresistance.Methods: RNF6 levels in radioresistant and non-radioresistant CRC patients were detected. In vitro and in vivo regulatory effects of RNF6 on radioresistant CRC cell lines and nude mice bearing radioresistant CRC were examined, respectively. The involvement of Wnt pathway in CRC radioresistance was explored by Western blot.Results: RNF6 was highly expressed in radioresistant CRC species than that of non-radioresistant ones. Identically, RNF6 was upregulated in radioresistant CRC cells compared to parental cells. SW1116 cells overexpressing RNF6 were more tolerant to radiotherapy, and similar results were obtained in nude mice bearing radioresistant CRC with overexpression of RNF6. Moreover, the Wnt pathway was activated during RNF6-induced radioresistance improvement in CRC.Conclusions: RNF6 enhances radioresistance of CRC through activating the Wnt pathway.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: RNF6 is verified to promote the malignant growth of colorectal cancer (CRC) and its level is linked to prognosis in CRC patients. Radioresistance is a key factor influencing prognosis in CRC. This study aimed to uncover the potential regulation of ring finger protein 6 (RNF6) in CRC radioresistance.

Methods: RNF6 levels in radioresistant and non-radioresistant CRC patients were detected. In vitro and in vivo regulatory effects of RNF6 on radioresistant CRC cell lines and nude mice bearing radioresistant CRC were examined, respectively. The involvement of Wnt pathway in CRC radioresistance was explored by Western blot.

Results: RNF6 was highly expressed in radioresistant CRC species than that of non-radioresistant ones. Identically, RNF6 was upregulated in radioresistant CRC cells compared to parental cells. SW1116 cells overexpressing RNF6 were more tolerant to radiotherapy, and similar results were obtained in nude mice bearing radioresistant CRC with overexpression of RNF6. Moreover, the Wnt pathway was activated during RNF6-induced radioresistance improvement in CRC.

Conclusions: RNF6 enhances radioresistance of CRC through activating the Wnt pathway.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

RNF6通过激活Wnt通路增强结直肠癌的放射耐药。

目的:研究证实RNF6可促进结直肠癌(CRC)的恶性生长，其表达水平与CRC患者预后相关。放射耐药是影响结直肠癌预后的关键因素。本研究旨在揭示环指蛋白6 (ring finger protein 6, RNF6)在结直肠癌放射耐药中的潜在调控作用。方法:检测放射耐药和非放射耐药结直肠癌患者RNF6水平。研究了RNF6对CRC放射耐药细胞系和裸鼠的体内和体外调控作用。Western blot方法探讨Wnt通路在结直肠癌放射耐药中的作用。结果:RNF6在辐射耐药结直肠癌品种中表达高于非辐射耐药结直肠癌品种。同样，与亲本细胞相比，RNF6在辐射耐药的CRC细胞中上调。过表达RNF6的SW1116细胞对放疗的耐受性更强，在RNF6过表达的放射耐药结直肠癌裸鼠中也获得了类似的结果。此外，在rnf6诱导的CRC耐药改善过程中，Wnt通路被激活。结论:RNF6通过激活Wnt通路增强CRC的放射耐药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.